Hortal M, Estevan-Collazo M, Meny M

Language: Spanish
References: 11
Page: 97-99
PDF size: 201.60 Kb.

ABSTRACT

Introduction: Streptococcus pneumoniae etiology is poorly defined in children’s pneumonia. To overcome this problem, the World Health Organization recommended standardized chest radiograph interpretation as an epidemiological marker to provide a reasonable approach to bacterial pneumonia (presumed pneumococcal). Pneumococcal conjugate vaccine application reduced the incidence of consolidated pneumonias in hospitalized children, but a reduction was also recorded among non-consolidated pneumonias. Therefore, C-reactive protein (CRP) was proposed as an additional marker. Objective: To assess the frequency of CRP ≥ 40 mg/L associated with pneumonias among hospitalized children. Methods: Retrospective data abstracted from clinical reports provided C-reactive protein results and chest x-ray classifications. Significant cut off for CRP serum concentration was ≥ 40 mg/L. Results: Among patients with consolidated pneumonia, CRP high values predominated, but significant values were also associated with non-consolidated pneumonias. Pneumococcal pneumonias and pleural effusions showed high CRP levels. Conclusion: The recorded CRP results associated with chest X-ray interpretations point to a potential participation of S. pneumoniae in pediatric pneumonias. A prospective study is needed to further explore the potential contribution of both markers for bacterial pneumonia estimation.

REFERENCES

1. World Health Organization Pneumonia Vaccine Trial Investigator’s Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. Geneva: World Health Organization; 2001.

2. Hortal M, Estevan M, Iraola I, De Mucio B. A population-based assessment of the disease burden of consolidated pneumonia in hospitalized children under five years of age. Intl J Infect Dis. 2007; 11: 273-277.

3. Hortal M, Estevan M, Laurani H, Iraola I, Meny M, Paysandú/Salto Study Group. Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine. 2012; 30: 4934-4938.

4. Zhou H, Haber M, Ray S, Farley M, Panozzo C, Klugman K. Invasive pneumococcal pneumonia and respiratory virus co-infections. Emerg Infect Dis. 2012; 18: 294-297.

5. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J. 2001; 20: 951-958.

6. McIntosh EDG, Booy R. Invasive pneumococcal disease in England and Wales, what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine? Arch Dis Child. 2002; 86: 403-406.

7. Madhi SA, Klugman KP, the Vaccine Trialist Group. A role for Streptococcus pneumonia in virus-associated pneumonia. Nat Med. 2004; 10: 811-813.

8. Madhi SA, Kohler M, Kuwanda L, Cutland C, Klugman KP. Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediat Infect Dis J. 2006; 25: 30-36.

9. Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Resp Dis. 1987; 135: 869-874.

10. Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in differenciating bacterial from non bacterial pneumonia in children. A meta-analysis of 1230 children. Pediatr Infect Dis J. 2008; 27: 95-99.

11. The Perch Study Group. Elevated CRP is associated with bacterial pneumonia in children but may not distinguish pneumococcal from other bacterial pneumonia. Pneumonia (Special issue) 2014; 2: 262.